These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 29545396)
1. Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction? Michalak M; Armstrong PW Circ Heart Fail; 2018 Mar; 11(3):e004813. PubMed ID: 29545396 [No Abstract] [Full Text] [Related]
2. The effects of cyclic guanylate cyclase stimulation on right ventricular hypertrophy and failure alone and in combination with phosphodiesterase-5 inhibition. Andersen A; Nielsen JM; Holmboe S; Vildbrad MD; Nielsen-Kudsk JE J Cardiovasc Pharmacol; 2013 Aug; 62(2):167-73. PubMed ID: 23575263 [TBL] [Abstract][Full Text] [Related]
3. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. Boerrigter G; Burnett JC Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086 [TBL] [Abstract][Full Text] [Related]
4. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle. Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622 [TBL] [Abstract][Full Text] [Related]
5. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure. Liang WL; Liang B Curr Cardiol Rep; 2023 Jun; 25(6):607-613. PubMed ID: 37079245 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of the relaxant effect of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in isolated detrusor smooth muscle. Báu FR; Mónica FZ; Priviero FB; Baldissera L; de Nucci G; Antunes E Eur J Pharmacol; 2010 Jul; 637(1-3):171-7. PubMed ID: 20399768 [TBL] [Abstract][Full Text] [Related]
7. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure. Breitenstein S; Roessig L; Sandner P; Lewis KS Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610 [TBL] [Abstract][Full Text] [Related]
8. Regulation of soluble guanylyl cyclase activity by oestradiol and progesterone in the hypothalamus but not hippocampus of female rats. Reyna-Neyra A; Sarkar G; Etgen AM J Neuroendocrinol; 2007 Jun; 19(6):418-25. PubMed ID: 17388815 [TBL] [Abstract][Full Text] [Related]
15. What is next in nitric oxide research? From cardiovascular system to cancer biology. Bian K; Murad F Nitric Oxide; 2014 Dec; 43():3-7. PubMed ID: 25153032 [TBL] [Abstract][Full Text] [Related]
16. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice. Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Mullershausen F; Russwurm M; Friebe A; Koesling D Circulation; 2004 Apr; 109(14):1711-3. PubMed ID: 15066950 [TBL] [Abstract][Full Text] [Related]